Shanghai Henlius Biotech has been given the green light to market its trastuzumab biosimilar (Zercepac, HLX02) in the European Union. Accord Healthcare will handle the distribution.
The European Commission (EC) has approved the marketing of the trastuzumab biosimilar Zercepac, developed by Shanghai Henlius Biotech and set to be marketed by Accord Healthcare, according to information released by the companies and the EC.
Zercepac (HLX02) is indicated for the treatment of early breast cancer following surgery or chemotherapy and radiotherapy; metastatic breast cancer alone or in combination with other medicines, such as paclitaxel or docetaxel or aromatase inhibitors; and metastatic gastric cancer in combination with cisplatin and either capecitabine or fluorouracil.
The biosimilar trastuzumab is intended for use only in cancers that are HER2-expressing, which is the case in about 25% of breast cancers and 20% of gastric cancers. The newly approved biosimilar references Herceptin.
Henlius is based in Shanghai, China, with research and development activities in California; and Accord is based in Ahmedabad, India, with a suburban office in North Harrow outside London, England.
International Standing for Henlius
Henlius has sought to develop international standing as a biosimilar company and in its statement today, officials said this approval demonstrates that the company is achieving that objective. “The approval of Zercepac in the EU is a significant milestone of our global strategy,” said Scott Liu, co-founder and CEO of Henlius. “This achievement announces that our capability in the development and manufacturing of biologics has reached international standards. In the future, Henlius will provide more high-quality biologics as new treatment options to benefit patients worldwide.”
“Henlius strictly followed the [China National Medical Products Administration] and [European Medicines Agency] guidelines and has [done] multiple head-to-head comparisons between Zercepac…and the reference trastuzumab, including comparative quality studies, preclinical studies, a phase 1 clinical study and a global multi-center phase 3 clinical study. [The] manufacturing site of Zercepac and its quality management system have obtained EU [Good Manufacturing Practices] certificates,” the company said.
For Accord, the trastuzumab product marks the company’s first monoclonal antibody and therefore raises the company’s profile in the world of complex biologics, according to Paul Tredwell, vice president of Specialty Brands for Accord.
“Zercepac is an exciting new addition to our growing oncology portfolio, which now provides access to over 30 high-quality, cost-effective oncology treatments to patients across Europe,” he said.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.